Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Lowered to $473.00 at JPMorgan Chase & Co.

Key Points

• JPMorgan Chase & Co. has lowered its price target for Alnylam Pharmaceuticals from $475.00 to $473.00, but maintains an "overweight" rating, indicating a potential upside of 2.81% from the company's previous close.
• Other analysts have varying perspectives, with Bank of America raising its target price to $520.00 while Barclays increased it to $460.00, collectively reflecting a strong consensus rating of “Moderate Buy.”
• Insider trading activity has been notable, with CEO Yvonne Greenstreet selling 8,924 shares amounting to over $4 million, resulting in a 12.01% reduction in their ownership stake.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) had its price target dropped by equities research analysts at JPMorgan Chase & Co. from $475.00 to $473.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage currently has an "overweight" rating on the biopharmaceutical company's stock. JPMorgan Chase & Co.'s target price indicates a potential upside of 2.81% from the company's previous close.

Several other research analysts also recently commented on ALNY. Bank of America raised their target price on Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the stock a "buy" rating in a research note on Wednesday, September 17th. Wells Fargo & Company upped their price objective on Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the company an "equal weight" rating in a research report on Friday, August 1st. Truist Financial initiated coverage on Alnylam Pharmaceuticals in a research note on Monday, July 21st. They issued a "buy" rating and a $385.00 price objective for the company. Barclays increased their price target on shares of Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the company an "overweight" rating in a report on Friday, August 1st. Finally, Citigroup increased their price objective on shares of Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the stock a "buy" rating in a research report on Tuesday, September 2nd. Twenty-four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $457.08.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY traded down $0.40 during midday trading on Monday, hitting $460.06. 36,149 shares of the company's stock were exchanged, compared to its average volume of 976,159. The firm has a market capitalization of $60.30 billion, a PE ratio of -187.13 and a beta of 0.36. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10. The company's 50 day moving average price is $451.37 and its 200 day moving average price is $346.13. Alnylam Pharmaceuticals has a 12 month low of $205.87 and a 12 month high of $484.21.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The business had revenue of $773.69 million during the quarter, compared to analysts' expectations of $633.54 million. During the same quarter in the prior year, the firm earned ($0.13) EPS. The business's revenue for the quarter was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, analysts predict that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 8,924 shares of the company's stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $4,034,094.20. Following the sale, the chief executive officer owned 65,409 shares in the company, valued at $29,568,138.45. This represents a 12.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Kevin Joseph Fitzgerald sold 2,441 shares of the stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $1,103,454.05. Following the completion of the sale, the executive vice president directly owned 25,231 shares in the company, valued at approximately $11,405,673.55. This trade represents a 8.82% decrease in their position. The disclosure for this sale can be found here. Insiders sold 98,144 shares of company stock valued at $44,160,261 over the last quarter. Company insiders own 1.50% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Congress Asset Management Co. bought a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $54,173,000. Riversedge Advisors LLC bought a new position in Alnylam Pharmaceuticals during the third quarter worth $215,000. Hilltop National Bank acquired a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth $41,000. Fiduciary Alliance LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth $243,000. Finally, Cooper Financial Group bought a new stake in Alnylam Pharmaceuticals during the third quarter worth about $272,000. Institutional investors and hedge funds own 92.97% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.